Weekly Digest: EU AI Act Prohibitions, GDPR Enforcement and Clinical Trial Developments - Week of 22 June 2026
Trending Articles
Latest Articles & News
Weekly Digest: EU AI Act Prohibitions, GDPR Enforcement and Clinical Trial Developments - Week of 22 June 2026
AI healthcare rules tighten as EU, US and GDPR developments accelerate.
CTIS Data Protection: Joint Controllership, GDPR Obligations and Sponsor Responsibilities
Understand CTIS data protection obligations under EU CTR 536/2014 and GDPR. Learn how the Joint Controllership Arrangement allocates roles among sponsors, EMA and Member States.
Pseudonymisation Clinical Trials: CNIL's Enforcement Clarifications and What They Mean for Life Sciences Organisations
CNIL's 2026 enforcement action clarifies the line between pseudonymisation and anonymisation in clinical trials. Learn the GDPR implications and recommended practices.
Weekly Privacy & AI Regulation Digest: Shadow AI, EDPB Templates, EHDS and Global Reform - Week of 16 June 2026
Shadow AI risks, EDPB breach and DPIA templates, the European Health Data Space, Canada's PIPEDA replacement and APAC consent divergence, this week's key updates.
DPIA Clinical Trials: How the EDPB Harmonised Template Reshapes Sponsor Obligations
The EDPB's 2026 harmonised DPIA template changes how sponsors conduct data protection impact assessments in clinical trials. Learn what it means for your programme.
Vendor GDPR in Clinical Trials: What the IQVIA CNIL Ruling Changes for Sponsors and Healthtech Companies
On 26 May 2026 the CNIL fined IQVIA Operations France EUR 5 million for failures in its two authorised health data warehouses, LRX and EMR. The decision exposes weaknesses in CRO data protection practice that have direct consequences for every pharmaceutical sponsor relying on a CRO to process patient, prescription or trial data. This article unpacks the four areas of failure, explains why pseudonymisation no longer offers the cover many sponsors assume, and sets out a practical oversight checklist for sponsor data controllers.
Sign up for our newsletter
We like to keep our readers up to date on complex regulatory issues, the latest industry trends and updated guidelines to help you to solve a problem or make an informed decision.
Sign up for our newsletter
We like to keep our readers up to date on complex regulatory issues, the latest industry trends and updated guidelines to help you to solve a problem or make an informed decision.
